Research output per year
Research output per year
Personal profile
Headline
PROFESSOR | Medicine, Hematology and Medical Oncology
Biography
Dr. Tiersten is a Professor in the Division of Hematology and Medical Oncology and a member of the Breast Cancer Medical Oncology Program. Dr. Tiersten sees patients in the Dubin Breast Center. She works collaboratively with Mount Sinai breast surgeons, radiation oncologists, radiologists, and other related subspecialists to provide care to breast cancer patients and conduct breast cancer research. Dr. Tiersten has extensive experience participating clinical trials, as well as being the Principal Investigator for national studies.
Fingerprint
Dive into the research topics where Amy Tiersten is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 6 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer
Knutson, K. L., Abu-Fares, H., Keating, P., Block, M. S., Norton, N., Erskine, C. L., Cogen, D., Assad, H., Graff, S. L., Hamilton, E. P., Han, H. S., McIntyre, K. J., Nassar, A., Sparano, J. A., Tiersten, A., Tkaczuk, K. H., Ward, P. J., Wilson, G., Garrett, G. & Kenney, R. T. & 1 others, , 1 Jan 2026, In: Clinical Cancer Research. 32, 1, p. 106-117 12 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer☆
The International Breast Cancer Study Group & SOFT and TEXT Investigators, 2026, (Accepted/In press) In: Annals of Oncology.Research output: Contribution to journal › Article › peer-review
Open Access -
Prescribing Trends of Adjuvant Neratinib in Hormone Receptor-Positive HER2-Positive Breast Cancer
Blanter, J., Kocyigit, H., Kowtha, L., Harigopal, M. & Tiersten, A., Aug 2026, In: Oncology (Switzerland). 104, 8, p. 925-928 4 p.Research output: Contribution to journal › Article › peer-review
-
Impact of race/ethnicity on MammaPrint genomic assay risk and prognosis in early breast cancer: A National Cancer Data Base analysis
Patel, R. B., Sheng, T., Diniz, M. A., Sparano, J. A. & Tiersten, A., 1 Mar 2025, In: Cancer. 131, 5, e35771.Research output: Contribution to journal › Article › peer-review
Open Access -
Institutional adherence to CDK4/6 inhibitor use in ER+/HER2- metastatic breast cancer: A retrospective cohort study.
Anyanwu, M. C., Wagner, N., Becerra, H., Siddiqui, W., Yao, I., Catlett, J. L., Okine, T., Esantsi, T. K., Kier, M. W. & Tiersten, A., 19 Nov 2025, In: JCO Oncology Practice. 21, p. 190 1 p.Research output: Contribution to journal › Article › peer-review
Press/Media
-
Could Some Metastatic Breast Cancer Patients Skip Chemotherapy?
3/09/26
1 item of Media coverage
Press/Media
-
-
Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer
27/08/26
1 item of Media coverage
Press/Media
-
Chemo-Free Treatment Shows Promise For Some Metastatic Breast Cancer Patients
25/08/26 → 26/08/26
5 items of Media coverage
Press/Media